Botox maker Allergan Plc said Monday it expects to book a pre-tax charge of $750 million in the third quarter after its Forest subsidiaries settled an antitrust class action suit brought by direct purchasers of Namenda, a treatment for dementia associated with Alzheimer’s disease. Forest will pay that sum to settle the suit, which was scheduled to go to trial in October. Forest became a wholly owned unit of Actavis Plc in June 2014, after which Actavis changed its name to Allergan.

Read the source article.